The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer; PharmaMar
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Pfizer
Other Relationship - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
 
Stephen J. Freedland
Employment - Genomic Health (I)
Consulting or Advisory Role - A3P Biomedical; Astellas Pharma; AstraZeneca; Bayer; Caper Labs; Clovis Oncology; Dendreon; Exact Sciences; Exosome Diagnostics; Ferring; Hessian Labs; Janssen Biotech; LynxDx; Merck; Myovant Sciences; Pfizer; Sanofi; Tempus
Speakers' Bureau - AstraZeneca; Sanofi
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Martin Gleave
No Relationships to Disclose
 
Ugo De Giorgi
No Relationships to Disclose
 
Antti Rannikko
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - AstraZeneca
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolmar
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Miguel Ramirez-Backhaus
Honoraria - Accolade; Astellas Pharma; Bayer; Ipsen; Janssen; Karl Storz
Consulting or Advisory Role - Accolade; Astellas Pharma; Bayer; Ipsen; Janssen; Karl Storz
Speakers' Bureau - Accolade; Astellas Pharma; Bayer; Ipsen; Janssen; Karl Storz
Travel, Accommodations, Expenses - Accolade; Astellas Pharma; Bayer; Ipsen; Janssen; Karl Storz
 
Anchen F. Nasr
Employment - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Jasmina I. Ivanova
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Arijit Ganguli
Employment - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Pavol Kral
Employment - IQVIA
Consulting or Advisory Role - Astellas Pharma (Inst)
 
Arlene Reisman
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Stock and Other Ownership Interests - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; Accord Research; AIkido Pharma; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; FerGene; Ferring; Fize Medical; Genesis Cancer Care; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring